The purpose of this study is to evaluate the safety and effects of an investigational drug called CUE-102 in cancer patients. The study will include patients who have colorectal, gastric, pancreatic or ovarian cancer that has returned after treatment and/or has spread beyond its original location to other parts of the body (metastasized) and for which no standard treatment currently exists. Researchers aim to determine whether treatment with CUE-102 activates the immune system to kill cancer cells safely and provides benefit that is better than currently available treatments. CUE-102 activates and increases the number of T cells, a type of immune cell, that are capable of killing tumor cells. CUE-102 has components that are unique for activating only those T cells that will recognize the tumor.
What is the full name of this clinical trial?
CUE-102-01: A Phase 1, Open-Label, Dose Escalation and Expansion Study of CUE-102 Monotherapy in HLA-A*0201 Positive Patients with WT1 Positive Recurrent / Metastatic Cancers